Wall Street analysts are maintaining Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) company shares. The one year target on the name currently stands at $45.00. The stock recently touched $18.93 and has moved in the range of $18.65 - 19.87 during the current session. Based on a recent bid this places the stock +13.76% away from the 52-week floor of $16.64 and -63.59% away from the 52-week ceiling of $51.99.
When stocks are given “Buy” ratings by analysts, the reasons or criteria for that recommendation can greatly vary. Typically when a stock is given this label, analysts are expecting that the stock will outperform their peers, their sector or the market over a 6 to 12 month time frame. Several factors might include near-term catalysts, future earnings growth. Many analysts only give a Buy recommendation when they expect that the stock will yield a return of at least 5-10% over the course of a year. Since analyst criteria and recommendation terminology can differ, we can look at consensus numbers to get a feel of overall analyst sentiment.
Green Plains, Inc. (NASDAQ:GPRE) has been given a consensus Buy rating by analysts on Wall Street. According to Thomson Reuters' First Call, research brokers have a one year price target of $20.27 on the stock. The stock is currently trading -27.11% away from its 200-day moving average of $19.39. Based on a recent trade, shares of Green Plains, Inc. are -58.50% away from the 52-week high of $34.05 and +14.04% away from the 52-week low of $12.39.
Analysts are estimating that the company will report earnings of $0.49 for the current year and $-0.11 for next quarter. The stock closed the most recent trading session at $14.32.
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $29.80 price target and Buy rating according to the covering analysts. During today’s session the stock hit $16.72 or +1.15% from the previous close, while moving in the range of $15.84 - 16.80.
Shares of MediWound Ltd. (NASDAQ:MDWD) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $15.50 price target according to the covering analysts. During today’s session the stock hit $7.66 or -2.94% from the previous close, while moving in the range of $7.41 - 7.71. This puts the stock -29.04% away from the 52-week high of $10.47 and +48.60% away from the 52-week low of $5.00.
Exact definitions of a “Buy” rating can greatly vary depending on the equity research firm. The consensus rating simply provides an average of those recommendations. It's important to note that a “Buy” rating does not mean that every investor should acquire the stock. It is just a single factor among many that should be considered before making an investment decision.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
